Philip Morris International Inc
Change company Symbol lookup
Select an option...
PM Philip Morris International Inc
BHR Braemar Hotels & Resorts Inc
ESALY Eisai Co Ltd
CNX CNX Resources Corp
WW WW International Inc
IBM International Business Machines Corp
NEP Nextera Energy Partners LP
TMP Tompkins Financial Corp
MFM MFS Municipal Income Trust

Consumer Staples : Tobacco | Large Cap Value
Company profile

Philip Morris International Inc. is a holding company. The Company is engaged in the manufacture and sale of cigarettes, other tobacco products and other nicotine-containing products in markets outside of the United States. Its segments include European Union (EU); Eastern Europe, Middle East & Africa (EEMA); Asia, and Latin America & Canada. The Company's portfolio of international and local brands is led by Marlboro. Its mid-price brands are L&M, Lark, Merit, Muratti and Philip Morris. Its other international brands include Bond Street, Chesterfield, Next and Red & White. The Company also owns various local cigarette brands, such as Dji Sam Soe, Sampoerna and U Mild in Indonesia; Champion, Fortune and Jackpot in the Philippines; Apollo-Soyuz and Optima in Russia; Morven Gold in Pakistan; Boston in Colombia; Belmont, Canadian Classics and Number 7 in Canada; f6 in Germany; Delicados in Mexico; Assos in Greece, and Petra in the Czech Republic and Slovakia.

Closing Price
Day's Change
-0.41 (-0.55%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

7:48 am ET September 14, 2020 (MarketWatch)

Eli Lily & Co. (LLY) and Incyte Corp. (INCY) said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s (GILD) remdesivir. Shares of Lily gained 0.7% in premarket trading on Monday, while Incyte's stock was up 1.4% and shares of Gilead were down 2.1%. The Food and Drug Administration (FDA) earlier this year authorized remdesivir as a treatment for some hospitalized COVID-19 patients, though the drug has not received a full approval at this time. A number of clinical trials are underway that are testing remdesivir in combination with other therapies, including Olumiant. The Phase 3, double-blind, randomized, controlled study testing Olumiant and remdesivir in 1,000 patients was sponsored by the National Institute of Allergy and Infectious Diseases NIAID); it found that adding Olumiant to the dosing regimen shortened recovery times by one day, when compared to prescribing remdesivir on its own. The full data from the trial was not disclosed in the press release. However, Lilly said the NIAID plans to publish the data in a peer-reviewed medical journal. Lilly said it plans to discuss an emergency use authorization (EUA) with the FDA and that it will propose the drug is sold "through commercial channels." (The EUA for remdesivir requires ( that the federal government distribute the drug.) Shares of Lilly are up 12.7% so far this year, while Incyte's stock has gained 0.8%. The S&P 500 is up 3.4% for the year.

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

September 14, 2020 07:48 ET (11:48 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.